Clinical trials
Liver Cirrhosis, Alcoholic clinical trials
Below are recruiting liver cirrhosis, alcoholic clinical trials, each written for real people, not researchers. We’re tracking 91 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07068191Recruiting
Gepaktiv vs other drugs for fatty liver with enlarged liver
This study tests a new drug, Gepaktiv, compared to two other treatments (UDCA and ademetionine) for people with metabolic fatty liver disease who also have an enlarged liver. You may be able to join if you meet specific test results showing moderate liver fat and scarring.
Tyumen, Tyumen OblastAges 18–65 - NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT06838468Enrolling by invitation
Study on liver health in alcohol detox patients
This study is looking at liver health in people staying in a detox unit for alcohol use disorder. Researchers want to see how common liver problems are in this group. Participating involves extra tests like blood work, an ultrasound, and a special liver scan (FibroScan).
Sabadell, BarcelonaAges 18–75 - NCT06519162Recruiting
Liver-gut link study for liver disease patients and their families
This study looks at how gut bacteria differ in people with specific liver diseases and their household contacts. It may help researchers understand the connection between the liver and gut.
Daejeon, Jung-guAges 19 years+ - NCT04858412Recruiting
Amino acid supplement to help people with COVID-19 and alcohol liver disease
This study tests whether an HMB-enriched amino acid supplement can improve outcomes in adults who have COVID-19 pneumonia, especially those with alcohol-related liver disease. The trial compares results in people with alcohol liver disease versus those without, to see if the supplement helps during recovery.
Cleveland, OhioAges 21 years+ - NCT06293378Recruiting
Sulfasalazine for liver fibrosis and cirrhosis
This study tests if sulfasalazine, a medicine already used for other conditions, is safe and helpful for people with liver scarring (fibrosis or cirrhosis). It is for patients with cirrhosis caused by certain liver diseases, like PBC, hepatitis B, hepatitis C, or alcohol use.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT06084234RecruitingPhase 4
National liver cancer screening trial
This trial is testing a new way to screen for liver cancer in people with cirrhosis or chronic hepatitis B. It aims to find cancer earlier so it can be treated more effectively.
Los Angeles, CaliforniaAges 18–85 - NCT04899102Recruiting
Intermittent fasting for fatty liver disease in adults
This study tests whether intermittent fasting can improve fatty liver disease (NAFLD) by reducing liver fat. It focuses on adults with confirmed fatty liver and extra liver fat seen on a special MRI scan.
Boston, MassachusettsAges 18 years+ - NCT07325526RecruitingPhase 2
Testing an experimental drug for liver cirrhosis caused by MASH
This study tests an investigational medicine (BI 3802876) in people with early-stage liver cirrhosis due to MASH. The goal is to see if it is well tolerated and potentially helpful.
Chandler, ArizonaAges 18–75 - NCT07308548RecruitingPhase 2
Testing HP515 for fatty liver disease (NASH/MASH)
This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT05045482RecruitingPhase 1
Study drug in people with cirrhosis from blocked bile flow
This Phase 1 trial studies how saroglitazar magnesium works in people with liver scarring (cirrhosis) caused by a bile-flow problem. It helps doctors understand safety and how the body handles the medicine in this specific liver condition.
Indianapolis, IndianaAges 18–80 - NCT07241195Recruiting
Fatty Liver Study in Older Adults
This study follows older adults with fatty liver disease to understand how their metabolism changes over time and how it affects their overall health. It helps researchers learn more about the condition and its impact on the body outside the liver.
Hangzhou, ZhejiangAges 65–100 - NCT07002827Recruiting
Growth factors for early decompensated cirrhosis
This study tests whether a combination of two medicines (G-CSF and darbepoetin) given in one or more cycles can improve the body's immune and metabolic health in people with early-stage decompensated cirrhosis (advanced liver disease with mild complications). It compares these treatments with standard medical care.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT06461208RecruitingPhase 3
Fecal transplant for people with cirrhosis
This trial tests whether transplanting healthy gut bacteria (from donor stool) can improve outcomes in people with cirrhosis. If you have mild to moderate cirrhosis, you may be able to join.
BasildonAges 18 years+ - NCT07265544Recruiting
Liver disease study using advanced tissue analysis
This study uses advanced techniques to analyze liver tissue samples from people with various liver conditions. It aims to better understand how liver diseases develop and progress, which may help improve future treatments.
Guangzhou, GuangdongAges Any age - NCT06455280RecruitingPhase 1
A study of Siplizumab for autoimmune liver disease patients awaiting transplant
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
New York, New YorkAges 18 years+ - NCT07658755Recruiting
LiverSeek: Finding advanced liver scarring in MASLD
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
Madrid, MadridAges 50–75 - NCT07046819RecruitingPhase 2
Tirzepatide for liver disease linked to alcohol use
This trial tests if tirzepatide, a medication that helps with weight and blood sugar, can improve liver health in people with alcohol use disorder who also have fatty liver disease. It aims to reduce liver fat and related risks.
Bethesda, MarylandAges 21–100 - NCT07172035Recruiting
TIPS and liver recovery in decompensated cirrhosis
This trial studies whether a procedure called TIPS (a stent placed in the liver to improve blood flow) can help people with advanced liver disease regain better liver function. It is for patients who have had complications like severe bleeding from the stomach or difficult-to-control fluid buildup (ascites).
ChangshaAges 18–80 - NCT04873102RecruitingPhase 2
Danazol for low blood counts in some people with cirrhosis
This Phase 2 study tests danazol to improve low blood counts (low white blood cells and/or low platelets) in people with certain types of cirrhosis. It also looks at who may benefit, especially those with specific inherited blood-telomere changes.
Los Angeles, CaliforniaAges 18 years+ - NCT05982769Recruiting
Exercise for cirrhosis patients
This study tests whether a supervised exercise program can help people with cirrhosis (scarred liver) feel stronger and improve their health. You'll be asked to exercise regularly and have tests to see how your muscles and liver respond.
Cleveland, OhioAges 21–65 - NCT03208868Recruiting
Amino acid drink to help rebuild muscle in cirrhosis
This trial tests whether a special mix of amino acids (building blocks for muscle) can help reverse muscle loss in people with cirrhosis. It aims to improve muscle health while keeping you safe from known complications of liver disease.
Cleveland, OhioAges 18–70 - NCT03773887Recruiting
Study of liver inflammation and healing in alcohol-related liver disease
This study compares patterns of liver inflammation and the liver’s healing ability in people with alcohol-related liver disease, using blood tests and (in most cases) a liver tissue sample. It may help doctors better understand what is happening in the liver and how it may recover.
LilleAges 18–70 - NCT03025074Recruiting
Blood sample bank for liver disease research
This study collects blood samples to build a “biobank” (a stored library of samples) for researchers studying liver diseases like hepatitis, fatty liver disease, and liver cancer. It may help future testing and treatments by allowing scientists to study patterns in people with and without liver conditions.
Buffalo, New YorkAges 7 years+
Hear when a new Liver Cirrhosis, Alcoholic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cirrhosis, alcoholic?
- Yes. Clin2 currently lists 91 recruiting liver cirrhosis, alcoholic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cirrhosis, alcoholic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cirrhosis, alcoholic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.